BIOLASE, Inc. Quarterly report pursuant to Section 13 or 15(d)

Convertible Redeemable Preferred Stock And Stockholders' Equity (Deficit) - Summary our stock warrants measured at fair value (Details)

Convertible Redeemable Preferred Stock And Stockholders' Equity (Deficit) - Summary our stock warrants measured at fair value (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Temporary Equity And Stockholders Equity [Line Items]
Beginning Balance, December 31, 2023	$ 1,363
Fair Value Adjustment	(1,060)	$ (104)
Ending Balance, September 30, 2024	1,437
Fair value recurring \| Level 3
Temporary Equity And Stockholders Equity [Line Items]
Beginning Balance, December 31, 2023	1,363
Additions	3,851
Exercises	(2,055)
Expiration / Exchange	(632)
Fair Value Adjustment	(1,090)
Ending Balance, September 30, 2024	1,437
Series H Warrants [Member] \| Fair value recurring \| Level 3
Temporary Equity And Stockholders Equity [Line Items]
Beginning Balance, December 31, 2023	620
Fair Value Adjustment	127
Ending Balance, September 30, 2024	747
Series J Warrants [Member] \| Fair value recurring \| Level 3
Temporary Equity And Stockholders Equity [Line Items]
Beginning Balance, December 31, 2023	743
Exercises	(95)
Expiration / Exchange	(632)
Fair Value Adjustment	(16)
Ending Balance, September 30, 2024	0
Class A Common Warrants [Member] \| Fair value recurring \| Level 3
Temporary Equity And Stockholders Equity [Line Items]
Additions	2,280
Exercises	(1,960)
Fair Value Adjustment	(177)
Ending Balance, September 30, 2024	143
Class B Common Warrants [Member] \| Fair value recurring \| Level 3
Temporary Equity And Stockholders Equity [Line Items]
Additions	1,379
Fair Value Adjustment	(899)
Ending Balance, September 30, 2024	480
Investor Warrants \| Fair value recurring \| Level 3
Temporary Equity And Stockholders Equity [Line Items]
Additions	192
Fair Value Adjustment	(125)
Ending Balance, September 30, 2024	$ 67